Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | NPEPPS | P55786 | 2/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23935898 | 0.84 | GAA (0.50) | GAALMNAMETTP53MAPT | |
| SCHEMBL23935866 | 0.80 | GRM2 (0.46) | LMNAMETNPEPPSMAPTGRM2 | |
| SCHEMBL18379277 | 0.77 | TDP1 (0.39) | GAANPEPPSGRM2TDP1L3MBTL1 | |
| SCHEMBL8739002 | 0.77 | MAPT (0.46) | GAALMNANPEPPSPTPN1MAPT | |
| SCHEMBL13979671 | 0.77 | BRD4 (0.56) | MAPTBRD4TDP1L3MBTL1 | |
| SCHEMBL13833580 | 0.77 | GAA (0.57) | GAALMNAPTPN1TP53MAPT | |
| SCHEMBL3238496 | 0.77 | GABRA1 (0.57) | LMNANPEPPS | |
| SCHEMBL18379974 | 0.76 | PTGS2 (0.45) | GAANPEPPSGRM2TDP1L3MBTL1 | |
| SCHEMBL8063482 | 0.76 | GAA (0.56) | GAALMNAMETPTPN1TP53 | |
| SCHEMBL5140683 | 0.76 | GAA (0.56) | GAALMNAPTPN1TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3456717-B1 | 4,6-DIAMINO-QUINOLINE-3-CARBONITRILE DERIVATIVE AS CANCER OSAKA THYROID (COT) MODULATOR FOR TREATING INFLAMMATORY DISEASE | GILEAD SCIENCES INC (US) | 2021-03-17 | — | — | EP | disclosed |
| US-20200392170-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392170-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | GAA 4381/4885LMNA 3781/4885MET 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.